Skip to main content
BrainCited

Acetyl-L-Carnitine für Age-Related Cognitive Decline

C

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Fazit

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

Key Study Findings

Randomized Controlled Trial
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …
Dose: None vs.: None Outcome: Cognitive decline Wirkung: None None

Population: Alzheimer's disease patients

Systematic Review
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: None

Review
Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: Chronic pain patients (preclinical review)

Review
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …
Dose: None vs.: None Outcome: None Wirkung: None None

Population: Parkinson's disease patients

Controlled Clinical Trial
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Dose: mitochondrial cofactors + antioxidants vs.: control diet Outcome: cognitive function in aged dogs Wirkung: improved learning and memory None

Population: Aged beagle dogs

Randomized Controlled Trial n=106 Double-blind
A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …
Dose: None vs.: placebo Outcome: None Wirkung: None p = 0.0083

Population: Alzheimer's disease patients

Key Statistics

14

Studien

1000

Teilnehmer

Positive

C

Bewertung

Referenced Papers

The Cochrane database … 2015 33 Zitierungen
The Cochrane database … 2003 94 Zitierungen
La Clinica terapeutica 1990 3 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
500-2,000 mg/day
cognitivesupport:
1,500-3,000 mg/day

Obergrenze: Well-tolerated up to 3,000 mg/day

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --
mitochondrial cofactors + antioxidants -- Positive --
None -- Positive 106
None -- Positive 427
None 8.0 weeks Positive --

Beste Einnahmezeit: Morning, on empty stomach or with meals

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Gastrointestinal discomfort (nausea, vomiting, diarrhea)
  • Fishy body odor
  • Restlessness or insomnia
  • Increased appetite

Bekannte Wechselwirkungen

  • Anticoagulants (may increase bleeding risk)
  • Thyroid medications (may enhance thyroid hormone effects)
  • AZT (antiretroviral — may reduce neuropathy)

Tolerierbare Höchstaufnahmemenge: Well-tolerated up to 3,000 mg/day

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?
Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).
How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acetyl-L-Carnitine?
Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?
We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.

Related Evidence

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.